All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View multiple myeloma content recommended for you
Mohamad MohtyAt the 24th Congress of the European Hematology Association (EHA), the Multiple Myeloma Hub spoke to Mohamad Mohty from the Hôpital Saint-Antoine, Paris, FR, about the role of autologous stem cell transplant (ASCT) in the future treatment of multiple myeloma (MM).
In this video, Professor Mohty summarizes the current status of ASCT in myeloma, stating it is a core part of the treatment pathway. He discuses smoldering myeloma, options for induction regimens, and then the potential future maintenance strategies that may impact patient care. Professor Mohty specifically refers to the potential of daratumumab, administered once every other month, to replace lenalidomide as maintenance therapy following ASCT. Professor Mohty concludes we will have to wait for the trial results, but that myeloma is "on the podium" at this year's EHA conference, with many interesting abstracts to be presented.
The role of autologous transplant in the future treatment of MM
Your opinion matters
Which of the following factors is most important to you when selecting a treatment for patients with multiple myeloma?